Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 1;21(1):863-879.
doi: 10.1007/s40200-021-00908-x. eCollection 2022 Jun.

Pharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review

Leyla Karkhaneh  1   2 , Ozra Tabatabaei-Malazy  3 , Fatemeh Bandarian  4 , Shahrzad Mohseni  5 , Bagher Larijani  5
Affiliations
Review

Pharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review

Leyla Karkhaneh et al. J Diabetes Metab Disord. .

Abstract

Purpose: Genetic factors have a role in response to a target medication (personalized medicine). This study aimed to review available evidence about the relationship between gene variants and therapeutic response to sulfonylureas in type 2 diabetes, systematically.

Methods: An extensive search was done in Scopus, PubMed, and Web of Science with specific search strategy in the field from the beginning until the 1st of Jan. 2021. After sending records to endnote software and removing duplicate records remained documents were screened by title and abstract. Full texts of remained documents were assessed after removing un-related records. Required data was extracted from remained documents and records were categorized according to gene/SNP studied.

Results: Finally, 26 studies with 9170 T2DM patients with a mean age of 59.47 ± 6.67 (49.7-75.2 years) remained. The most contribution was from China, Slovakia and Greece, respectively and the most genes studied were CYP2C9, KCNJ11, and both KCNQ1 and ABCC8 with 10, 7, and 4 articles, respectively. Also, rs1799853 and rs1057910 (each with seven studies), rs5219 with six studies and CYP2C9*1(with four articles), respectively were the most common variants investigated. Studies about each gene obtained different positive or negative results and were not consistent.

Conclusion: Considering heterogeneity between SFUs pharmacogenomic studies regarding the method, sample size, population, gene/variant studied, and outcome and findings, these studies are not conclusive and need further studies.

Keywords: Diabetes; Personalized medicine; Pharmacogenomics; Polymorphism; Sulfonylurea; Variant.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestAuthors have no conflict of interest to declare.

Figures

Fig. 1
Fig. 1
PRISMA flowchart for proccess of searching and analysis
Fig. 2
Fig. 2
Contribution of each country in SFUs phamacogenomic studies
Fig. 3
Fig. 3
Trend of publications about SFUs pharmacogenomic in type 2 diabetes patients during the past two decades
Fig. 4
Fig. 4
Distribution of genotyping methods in the included SFUs pharmacogenomic studies
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. International Diabetes Federation. IDF Diabetes Atlas. 2019: Brussels; Belgium.
    1. García-Chapa EG, Leal-Ugarte E, Jebari S, Larrea-Seba A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21:6275. - PMC - PubMed
    1. Akhondzadeh S. Personalized medicine: a tailor made medicine. Avicenna J Med Biotechnol. 2014;6:191. - PMC - PubMed
    1. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011;63:437–459. - PubMed
    1. Ahmed S, Zhou Z, Zhou J, Chen S-Q. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genom Proteom Bioinform. 2016;14:298–313. - PMC - PubMed

LinkOut - more resources